person · Reporting owner

WYZGA MICHAEL S

Disclosed activity across 8 companies

Tapewire entity: 39203
SEC CIK: 0001201256

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akebia Therapeutics, Inc.AKBA · Entity 6105	Director	June 14, 2018	June 15, 2018
EXACT SCIENCES CORPEXAS · Entity 56619	Director	February 26, 2021	March 02, 2021
Invivyd, Inc.IVVD · Entity 721	Director	May 23, 2023	May 25, 2023
Mereo BioPharma Group plcMREO · Entity 7264	Director	February 26, 2026	February 27, 2026
OncoMed Pharmaceuticals IncOMED · Entity 158190	Director	June 22, 2018	June 25, 2018
Tvardi Therapeutics, Inc.TVRD · Entity 7579	Director	June 09, 2026	June 11, 2026
X4 Pharmaceuticals, IncXFOR · Entity 5638	Director	January 01, 2026	January 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akebia Therapeutics, Inc.

Report date June 14, 2018 · Filed June 15, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14	Direct	12,500	Reported balance After 2018-06-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.

EXACT SCIENCES CORP

Report date February 26, 2021 · Filed March 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,558	Ending reported balance After 2021-02-26 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2021-02-26 · Exercise / conversion · Acquired 10,108 · Balance 21,579 F1: Represents shares of common stock received upon exercise of a stock option award. Row 2 · 2021-02-26 · Sale · Disposed 19,021 · Balance 2,558 F2: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.98	Direct	0	Reported balance After 2021-02-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-02-26 · Exercise / conversion · Disposed 10,108 · Balance 0 F3: These options vested and became exercisable on February 9, 2016.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock received upon exercise of a stock option award.

F2: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan.

F3: These options vested and became exercisable on February 9, 2016.

Invivyd, Inc.

Report date May 23, 2023 · Filed May 25, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2033-05-22	Direct	50,000	Reported balance After 2023-05-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-05-23 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.

Mereo BioPharma Group plc

Report date February 26, 2026 · Filed February 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26	Direct	66,000	Reported balance After 2026-02-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.

F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

OncoMed Pharmaceuticals Inc

Report date June 22, 2018 · Filed June 25, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2028-06-22	Direct	15,000	Reported balance After 2018-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Tvardi Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08	Direct	6,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

X4 Pharmaceuticals, Inc

Report date January 01, 2026 · Filed January 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2036-01-01	Direct	0	Reported balance After 2026-01-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-01 · Grant · Acquired 110,000 · Balance 0 F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

LogicBio Therapeutics, Inc.

Report date November 16, 2022 · Filed November 18, 2022

Section 16 reporting ended · disclosed 2022-11-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-11-16 transaction · row 1 1 source row Row 1 · 2022-11-16 · Disposition to issuer · Disposed 3,141 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-06-17	Direct	0	Reported balance After 2022-11-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-11-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F2: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.

F2: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.

F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 09, 2026 Filed Jun 11, 2026 20:30 UTC	Tvardi Therapeutics, Inc. TVRD · Entity 7579	GrantStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $2.78	$0.00	Disclosure SEC source: 0001201256-26-000003 · form4-06112026_040613.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	66,000	$0.00 Strike: $0.39	$0.00	Disclosure SEC source: 0001193125-26-082815 · ownership.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: American Depositary Shares · 66,000 shares Expires 2036-02-26 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
January 01, 2026 Filed Jan 5, 2026 21:05 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	110,000	$0.00 Strike: $4.00	$0.00	Disclosure SEC source: 0001501697-26-000006 · wk-form4_1767647121.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. Read SEC document
June 09, 2025 Filed Jun 10, 2025 20:25 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantCommon Stock	1,500	$0.00	$0.00	Disclosure SEC source: 0001628280-25-030489 · wk-form4_1749587118.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,555 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document
April 17, 2025 Filed Apr 21, 2025 21:15 UTC	Tvardi Therapeutics, Inc. TVRD · Entity 7579	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $17.04	$0.00	Disclosure SEC source: 0001415889-25-011110 · form4-04212025_050409.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2035-04-16 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable over three years in 12 equal quarterly installments commencing on July 17, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
April 15, 2025 Filed Apr 17, 2025 22:50 UTC	Tvardi Therapeutics, Inc. TVRD · Entity 7579	GrantStock Option (right to buy) · Derivative	18,441	Not disclosed Strike: $4.70	Not disclosed	Disclosure SEC source: 0001415889-25-010982 · form4-04172025_060413.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,441 Underlying: Common Stock · 18,441 shares Expires 2031-12-15 F2 · price: Received in exchange for a stock option to acquire 137,500 shares of common stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement"). F3 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F1 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	30,487	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-015418 · ownership.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,487 Underlying: American Depository Shares · 30,487 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document
February 05, 2025 Filed Feb 6, 2025 21:30 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	55,000	$0.00 Strike: $3.16	$0.00	Disclosure SEC source: 0000950170-25-015418 · ownership.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: American Depositary Shares · 55,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer Read SEC document
June 17, 2024 Filed Jun 17, 2024 20:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantAmerican Depositary Shares representing Ordinary Shares	25,050	$3.99	$99,949.50	Disclosure SEC source: 0000950170-24-074248 · ownership.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,050 F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
June 10, 2024 Filed Jun 11, 2024 20:12 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantCommon Stock	45,000	$0.00	$0.00	Disclosure SEC source: 0001628280-24-027671 · wk-form4_1718136724.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantDeferred Restricted Stock Units · Derivative	30,783	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-013266 · ownership.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,783 Underlying: American Depository Shares · 30,783 shares Expires not disclosed F3 · derivative.exercise_price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · price: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.exercise_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F3 · derivative.expiration_date: Deferred restricted stock units ("DRSU") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
February 08, 2024 Filed Feb 9, 2024 21:15 UTC	Mereo BioPharma Group plc MREO · Entity 7264	GrantShare Options (Right to buy) · Derivative	45,000	$0.00 Strike: $3.87	$0.00	Disclosure SEC source: 0000950170-24-013266 · ownership.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: American Depository Shares · 45,000 shares Expires 2034-02-08 F1 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Read SEC document
August 18, 2023 Filed Aug 22, 2023 20:09 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	PurchaseCommon Stock	25,000	$1.20	$29,875.00	Disclosure SEC source: 0001628280-23-030224 · wk-form4_1692734960.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,667 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in two transactions at $1.195 and $1.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote. F2 · balance_after: Of the shares of common stock reported, 48,333 shares represent restricted stock units. Read SEC document
June 13, 2023 Filed Jun 14, 2023 20:59 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantCommon Stock	45,000	$0.00	$0.00	Disclosure SEC source: 0001628280-23-022091 · wk-form4_1686776347.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document
May 23, 2023 Filed May 25, 2023 22:43 UTC	Invivyd, Inc. IVVD · Entity 721	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0000899243-23-013918 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-05-22 F1 · derivative.exercise_date: This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
November 16, 2022 Filed Nov 18, 2022 02:11 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	Disposition to issuerStock Option (right to buy) · Derivative	12,500	Not disclosed Strike: $0.38	Not disclosed	Disclosure SEC source: 0000899243-22-036301 · doc4.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F3 · price: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F2 · derivative.exercise_date: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document
November 16, 2022 Filed Nov 18, 2022 02:11 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	Disposition to issuerCommon Stock	3,141	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-036301 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes. Read SEC document
June 22, 2022 Filed Jun 24, 2022 20:35 UTC	Invivyd, Inc. ADGI · Entity 721	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $3.09	$0.00	Disclosure SEC source: 0000899243-22-024012 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option was granted on June 22, 2022 and vests in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to continued service through the vesting date. Read SEC document
June 17, 2022 Filed Jun 21, 2022 12:20 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $0.38	$0.00	Disclosure SEC source: 0001209191-22-038242 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document
June 06, 2022 Filed Jun 27, 2022 20:16 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantCommon Stock	6,667	$0.00	$0.00	Disclosure SEC source: 0001628280-22-018052 · wf-form4_165636098273574.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document
August 05, 2021 Filed Aug 9, 2021 23:54 UTC	Invivyd, Inc. ADGI · Entity 721	GrantStock Option (Right to Buy) · Derivative	71,186	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0001209191-21-050488 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,186 Underlying: Common Stock · 71,186 shares Expires 2031-08-04 F1 · derivative.exercise_date: One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date. Read SEC document
June 11, 2021 Filed Jun 15, 2021 00:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $4.59	$0.00	Disclosure SEC source: 0001209191-21-040426 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date. Read SEC document
June 02, 2021 Filed Jun 2, 2021 21:03 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	6,000	$9.50 Strike: $9.50	$57,000.00	Disclosure SEC source: 0001628280-21-011545 · wf-form4_162266780108629.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document
February 26, 2021 Filed Mar 2, 2021 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionStock Option (right to buy) · Derivative	10,108	$0.00 Strike: $26.98	$0.00	Disclosure SEC source: 0001209191-21-016479 · doc4.xml · derivative · entry 3 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,108 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options vested and became exercisable on February 9, 2016. F3 · derivative.expiration_date: These options vested and became exercisable on February 9, 2016. Read SEC document
February 26, 2021 Filed Mar 2, 2021 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	19,021	$130.11	$2,474,822.31	Disclosure SEC source: 0001209191-21-016479 · doc4.xml · nonDerivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,558 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 26, 2021 Filed Mar 2, 2021 19:00 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	10,108	$26.98	$272,713.84	Disclosure SEC source: 0001209191-21-016479 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document
January 01, 2021 Filed Jan 5, 2021 00:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	Exercise / conversionRestricted Stock Units · Derivative	3,141	$0.00	$0.00	Disclosure SEC source: 0001209191-21-000517 · doc4.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,141 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). F2 · derivative.exercise_date: All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. F2 · derivative.expiration_date: All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. Read SEC document
January 01, 2021 Filed Jan 5, 2021 00:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	Exercise / conversionCommon Stock	3,141	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-000517 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). Read SEC document
July 23, 2020 Filed Jul 24, 2020 16:36 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	2,558	$0.00	$0.00	Disclosure SEC source: 0001209191-20-043610 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,471 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document
June 19, 2020 Filed Jun 24, 2020 00:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantRestricted Stock Units · Derivative	3,141	$0.00	$0.00	Disclosure SEC source: 0001209191-20-038659 · doc4.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,141 Underlying: Common Stock · 3,141 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. F3 · derivative.expiration_date: All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. Read SEC document
June 19, 2020 Filed Jun 24, 2020 00:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0001209191-20-038659 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-19 F1 · derivative.exercise_date: All of the options will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of LogicBio Therapeutics, Inc. (the "Company") 2021 Annual Meeting of Stockholders, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan (the "2018 Plan"). Read SEC document
June 10, 2020 Filed Jun 11, 2020 12:28 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	3,427	$0.00 Strike: $8.69	$0.00	Disclosure SEC source: 0001628280-20-009236 · wf-form4_159187851570790.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document
December 19, 2019 Filed Dec 21, 2019 01:00 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantStock Option (right to buy) · Derivative	10,869	$0.00 Strike: $12.65	$0.00	Disclosure SEC source: 0001209191-19-061664 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,869 Underlying: Common Stock · 10,869 shares Expires 2029-12-19 F1 · derivative.exercise_date: 100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders. Read SEC document
July 31, 2019 Filed Aug 2, 2019 16:25 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $26.98	$0.00	Disclosure SEC source: 0001209191-19-044255 · doc4.xml · derivative · entry 3 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,108 Underlying: Common Stock · 2,500 shares Expires 2025-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 31, 2019 Filed Aug 2, 2019 16:25 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	5,000	$117.93	$589,650.00	Disclosure SEC source: 0001209191-19-044255 · doc4.xml · nonDerivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,913 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 29, 2018 to cover certain tax liabilities arising out of the vesting of shares of restricted stock. Read SEC document
July 31, 2019 Filed Aug 2, 2019 16:25 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	Exercise / conversionCommon Stock	2,500	$26.98	$67,450.00	Disclosure SEC source: 0001209191-19-044255 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document
July 25, 2019 Filed Jul 26, 2019 17:01 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	2,801	$0.00	$0.00	Disclosure SEC source: 0001209191-19-043380 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document
March 13, 2019 Filed Mar 15, 2019 01:31 UTC	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	70,324	Not disclosed Strike: $10.44	Not disclosed	Disclosure SEC source: 0000899243-19-007824 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,324 Underlying: Common Stock · 70,324 shares Expires 2028-08-21 F2 · price: Reflects the Reporting Person's stock option to acquire 740,000 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on August 22, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
March 13, 2019 Filed Apr 2, 2019 23:59 UTC Amendment	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	6,854	$0.00 Strike: $18.66	$0.00	Disclosure SEC source: 0000899243-19-009669 · doc4a.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2029-03-13 F3 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on March 13, 2020, with the remainder vesting in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the award, subject to the Reporting Person continuing to provide service through each such date. This amendment is being filed solely to report this additional stock option grant, which was granted automatically on March 13, 2019 pursuant to the Issuer's Director Compensation Policy upon such Reporting Person's election to the Board of Directors of the Issuer in connection with the closing of the Merger. Read SEC document
March 13, 2019 Filed Apr 2, 2019 23:59 UTC Amendment	X4 Pharmaceuticals, Inc XFOR · Entity 5638	GrantStock Option (right to buy) · Derivative	70,324	Not disclosed Strike: $10.44	Not disclosed	Disclosure SEC source: 0000899243-19-009669 · doc4a.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,324 Underlying: Common Stock · 70,324 shares Expires 2028-08-21 F2 · price: Reflects the Reporting Person's stock option to acquire 740,000 shares of X4 common stock for $0.99 per share that was assumed by the Issuer in the merger of Artemis AC Corp., a wholly-owned subsidiary of the Issuer, with and into X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) ("X4") on March 13, 2019 (the "Merger"). F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vested on August 22, 2019, and one thirty-sixth (1/36th) of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
February 28, 2019 Filed Mar 1, 2019 17:34 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	500	$96.00	$48,000.00	Disclosure SEC source: 0001209191-19-015127 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,612 F1 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 18, 2018 Filed Oct 23, 2018 01:13 UTC	LogicBio Therapeutics, Inc. LOGC · Entity 122292	GrantStock Option (right to buy) · Derivative	24,102	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0000899243-18-027213 · doc4.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,102 Underlying: Common Stock · 24,102 shares Expires 2028-10-17 F1 · derivative.exercise_date: The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, October 18, 2018. Read SEC document
August 28, 2018 Filed Aug 30, 2018 17:26 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	2,468	$74.85	$184,729.80	Disclosure SEC source: 0001209191-18-048986 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,112 F1 · shares: The sales reported in this Column 4 were effected to cover anticipated tax liabilities arising out of stock compensation. The reporting person adopted a Rule 10b5-1 Trading Plan pursuant to which these sales would have occurred on or about July 27, 2018 but due to administrative error the sales did not occur as initially planned. Read SEC document
July 26, 2018 Filed Jul 30, 2018 19:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantDeferred Stock Units · Derivative	3,230	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-044485 · doc4.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,230 Underlying: Common Stock · 3,230 shares Expires not disclosed F2 · security: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. F3 · derivative.expiration_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. Read SEC document
July 26, 2018 Filed Jul 30, 2018 19:46 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	606	$0.00	$0.00	Disclosure SEC source: 0001209191-18-044485 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,580 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document
June 22, 2018 Filed Jun 25, 2018 18:11 UTC	OncoMed Pharmaceuticals Inc OMED · Entity 158190	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $2.55	$0.00	Disclosure SEC source: 0001140361-18-029843 · doc1.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document
June 14, 2018 Filed Jun 15, 2018 12:17 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantStock Option (Right to buy) · Derivative	12,500	$0.00 Strike: $11.14	$0.00	Disclosure SEC source: 0001562180-18-003020 · primarydocument.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-14 F1 · shares: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. Read SEC document
May 10, 2018 Filed May 11, 2018 16:48 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	SaleCommon Stock	7,402	$51.53	$381,447.27	Disclosure SEC source: 0001209191-18-029603 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,974 F1 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.16 to $51.795, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document
July 27, 2017 Filed Jul 31, 2017 17:25 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantDeferred Stock Units · Derivative	5,273	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-046749 · doc4.xml · derivative · entry 2 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,273 Underlying: Common Stock · 5,273 shares Expires not disclosed F2 · security: Represents deferred stock unit award issued pursuant to the Company's non-employee director compensation policy. Each deferred stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. F3 · derivative.expiration_date: These deferred stock units vest in full on the first anniversary of the grant date or, if earlier, the date of the next annual meeting of the Company's stockholders. Deferred stock units that become earned and vested are payable upon separation of service. Read SEC document
July 27, 2017 Filed Jul 31, 2017 17:25 UTC	EXACT SCIENCES CORP EXAS · Entity 56619	GrantCommon Stock	791	$0.00	$0.00	Disclosure SEC source: 0001209191-17-046749 · doc4.xml · nonDerivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,376 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.